Kyongbo Pharmaceutical Co Ltd (214390) — Capital Reinvestment Ratio
Latest as of September 2025:
3.78x
Kyongbo Pharmaceutical Co Ltd (214390) has a Capital Reinvestment Ratio of 3.78x as of September 2025, meaning it reinvests 4% of its operating cash flow (₩4.51 Billion) in capital expenditures (₩17.04 Billion). See 214390 free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.
Capital Reinvestment Ratio
3.78x
Capex / Operating Cash Flow
Operating Cash Flow
₩4.51 Billion
KRW
Capital Expenditures
₩17.04 Billion
KRW
Data as of
Sep 2025
Most recent filing
Kyongbo Pharmaceutical Co Ltd Capital Reinvestment Ratio (2014–2024)
This chart tracks Kyongbo Pharmaceutical Co Ltd's Capital Reinvestment Ratio across 10 annual periods.
Annual Capital Reinvestment Ratio for Kyongbo Pharmaceutical Co Ltd (2014–2024)
Year-by-year Capital Reinvestment Ratio for Kyongbo Pharmaceutical Co Ltd from 2014 to 2024. For live market cap and broader valuation context, see Kyongbo Pharmaceutical Co Ltd stock valuation.
| Year | Reinvestment Ratio | Operating CF (KRW) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2024 | 88.35x | ₩149.12 Million | ₩13.18 Billion | ▲ +3835.0% |
| 2023 | 2.25x | ₩4.84 Billion | ₩10.88 Billion | ▲ +72.5% |
| 2022 | 1.30x | ₩10.13 Billion | ₩13.18 Billion | ▲ +27.7% |
| 2021 | 1.02x | ₩17.97 Billion | ₩18.32 Billion | ▲ +70.5% |
| 2020 | 0.60x | ₩20.80 Billion | ₩12.44 Billion | ▼ -39.1% |
| 2019 | 0.98x | ₩23.67 Billion | ₩23.25 Billion | ▲ +242.7% |
| 2017 | 0.29x | ₩25.81 Billion | ₩7.40 Billion | ▼ -63.1% |
| 2016 | 0.78x | ₩25.33 Billion | ₩19.68 Billion | ▼ -87.9% |
| 2015 | 6.43x | ₩4.24 Billion | ₩27.26 Billion | ▲ +434.9% |
| 2014 | 1.20x | ₩16.04 Billion | ₩19.28 Billion | — |
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow